文献速递肝病消化道出血

一项评估门静脉压力指导治疗预防肝硬化静脉曲张再出血能否改善生存的随机试验

A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis.
PubMed 文献 · Hepatology · 2017-03-30

本研究将肝硬化静脉曲张出血已控制的患者随机分为肝静脉压力梯度(HVPG)指导治疗组(84例)和对照组(86例),中位随访24个月。HVPG指导组死亡率29% vs 对照组43%(HR=0.59,95%CI=0.35-0.99),再出血率19% vs 31%(HR=0.53,95%CI=0.29-0.98),肝硬化进一步失代偿率52% vs 72%(HR=0.68,95%CI=0.46-0.99)。结论认为HVPG监测通过风险分层和目标治疗可改善生存。

要点

  • HVPG指导治疗组死亡率29%,低于对照组43%(HR=0.59,95%CI=0.35-0.99)。
  • HVPG指导组再出血率19%,低于对照组31%(HR=0.53,95%CI=0.29-0.98)。
  • HVPG指导组肝硬化进一步失代偿率52%,低于对照组72%(HR=0.68,95%CI=0.46-0.99)。

核心结论

  • HVPG监测通过风险分层和目标治疗,可改善当前推荐治疗(β受体阻滞剂联合套扎)预防静脉曲张再出血所达到的生存。
  • HVPG指导治疗实现更大程度的门静脉压力降低,可能有助于降低再出血风险和肝硬化进一步失代偿风险,从而改善生存。

研究设计与样本

  • 随机对照试验,纳入肝硬化静脉曲张出血已控制的患者,HVPG指导治疗组84例,对照组86例。
  • 两组均在基线和2-4周时评估HVPG及急性β受体阻滞剂反应以确定慢性应答。

主要发现

  • 中位随访24个月期间,HVPG指导组死亡率29% vs 对照组43%(HR=0.59,95%CI=0.35-0.99)。
  • 再出血率HVPG指导组19% vs 对照组31%(HR=0.53,95%CI=0.29-0.98)。
  • 肝硬化进一步失代偿率HVPG指导组52% vs 对照组72%(HR=0.68,95%CI=0.46-0.99)。
  • 急性无应答者中HVPG指导组生存概率高于对照组(HR=0.59,95%CI=0.32-1.08);慢性无应答者中HVPG指导组生存概率高于对照组(HR=0.48,95%CI=0.23-0.99)。
  • HVPG指导组HVPG降低幅度大于对照组,最终HVPG值低于对照组(P < 0.05)。

关键数值与推荐

  • HVPG指导组:急性应答者接受纳多洛尔治疗,急性无应答者接受纳多洛尔+硝酸酯类药物。
  • HVPG指导组:慢性无应答者接受纳多洛尔+哌唑嗪,并进行第三次HVPG检查。
  • 套扎治疗重复进行直至达到应答。
  • 对照组接受纳多洛尔+硝酸酯类药物+套扎治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Monitoring the hemodynamic response of portal pressure (PP) to drug therapy accurately stratifies the risk of variceal rebleeding (VRB). We assessed whether guiding therapy with hepatic venous pressure gradient (HVPG) monitoring may improve survival by preventing VRB. Patients with cirrhosis with controlled variceal bleeding were randomized to an HVPG-guided therapy group (N = 84) or to a control group (N = 86). In both groups, HVPG and acute β-blocker response were evaluated at baseline and HVPG measurements were repeated at 2-4 weeks to determine chronic response. In the HVPG-guided group, acute responders were treated with nadolol and acute nonresponders with nadolol+nitrates. Chronic nonresponders received nadolol+prazosin and had a third HVPG study. Ligation sessions were repeated until response was achieved. The control group was treated with nadolol+nitrates+ligation. Between-group baseline characteristics were similar. During long-term follow-up (median of 24 months), mortality was lower in the HVPG-guided therapy group than in the control group (29% vs. 43%; hazard ratio [HR] = 0.59; 95% confidence interval [CI] = 0.35-0.99). Rebleeding occurred in 19% versus 31% of patients, respectively (HR = 0.53; 95% CI = 0.29-0.98), and further decompensation of cirrhosis occurred in 52% versus 72% (HR = 0.68; 95% CI = 0.46-0.99). The survival probability was higher with HVPG-guided therapy than in controls, both in acute (HR = 0.59; 95% CI = 0.32-1.08) and chronic nonresponders (HR = 0.48; 95% CI = 0.23-0.99). HVPG-guided patients had a greater reduction of HVPG and a lower final value than controls (P < 0.05). CONCLUSION: HVPG monitoring, by stratifying risk and targeting therapy, improves the survival achieved with currently recommended treatment to prevent VRB using β-blockers and ligation. HVPG-guided therapy achieved a greater reduction in PP, which may have contributed to reduce the risk of rebleeding and of further decompensation of cirrhosis, thus contributing to a better survival. (Hepatology 2017;65:1693-1707).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Villanueva C, Graupera I, Aracil C, et al. A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis. Hepatology. 2017. PMID: 28100019. doi:10.1002/hep.29056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。